NuVasive (NSDQ:NUVA) announced that it added chief commercial officer and chief technology officer as new executive leadership roles.
Effective immediately, Massimo Calafiore will assume the position of chief commercial officer, while Ryan Donahoe was appointed as chief technology officer, with both reporting directly to CEO J. Christopher Barry. In connection with the new leadership structure, EVP of the company’s global commercial business Brent Boucher will transition from the company.
As CCO of the San Diego-based spine surgery tech company, Calafiore will oversee product marketing, commercial and commercial enablement functions, as well as the company’s specialized orthopedics and clinical services, according to a news release.
Calafiore joined NuVasive in 2017, most recently serving as EVP of global business units. He previously spent 16 years supporting and leading the U.S. business for Waldemar Link.
Donahoe, a 15-year veteran at NuVasive, will continue to lead the company’s spine research and development efforts. The company said he has played an integral role in shaping its procedurally integrated spine portfolio with more than 20 issued and pending patents.
“This new structure puts in place leaders who have decades of spine and orthopedics experience to advance our near- and long-term strategy as we continue to globalize and scale our business,” Barry said in the release. “I am confident Massimo’s and Ryan’s proven track records of building strong, effective teams and their commitment to our vision will help us deliver the strongest innovation pipeline in spine and increase value for our stakeholders.”